S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
S&P 500   2,995.68 (+1.00%)
DOW   27,024.80 (+0.89%)
QQQ   193.52 (+1.27%)
AAPL   235.32 (-0.23%)
FB   188.89 (+3.06%)
MSFT   141.58 (+1.45%)
GOOGL   1,242.24 (+2.01%)
AMZN   1,767.38 (+1.78%)
CGC   20.10 (+6.57%)
NVDA   196.37 (+5.28%)
MU   46.46 (+3.54%)
BABA   175.29 (+2.41%)
GE   8.89 (+1.95%)
TSLA   257.89 (+0.36%)
AMD   30.72 (+0.62%)
T   37.90 (+1.15%)
F   9.07 (+2.83%)
ACB   3.76 (+7.12%)
PRI   123.67 (+1.81%)
NFLX   284.25 (-0.45%)
BAC   29.73 (+2.02%)
GILD   65.30 (+1.22%)
DIS   129.76 (+0.05%)
Log in

Zymeworks Stock Price, News & Analysis (NYSE:ZYME)

$28.12
+0.12 (+0.43 %)
(As of 10/15/2019 04:00 PM ET)
Today's Range
$27.67
Now: $28.12
$28.38
50-Day Range
$24.44
MA: $26.53
$29.42
52-Week Range
$10.72
Now: $28.12
$29.75
Volume333,117 shs
Average Volume212,239 shs
Market Capitalization$1.11 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.34
Zymeworks Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I clinical trial for the treatment of breast and gastric cancer; ZW49, a bispecific antibody-drug conjugate that is in preclinical stage for treating breast and gastric cancers, and solid tumors. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:ZYME
CUSIPN/A
Phone604-678-1388

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$53.02 million
Book Value$5.64 per share

Profitability

Net Income$-36,560,000.00
Net Margins-102.78%

Miscellaneous

Employees180
Market Cap$1.11 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.


Zymeworks (NYSE:ZYME) Frequently Asked Questions

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

How were Zymeworks' earnings last quarter?

Zymeworks Inc (NYSE:ZYME) released its quarterly earnings results on Friday, August, 2nd. The company reported ($0.89) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.83) by $0.06. The business earned $7.88 million during the quarter, compared to the consensus estimate of $7.25 million. Zymeworks had a negative return on equity of 24.44% and a negative net margin of 102.78%. View Zymeworks' Earnings History.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Zymeworks.

What price target have analysts set for ZYME?

7 equities research analysts have issued twelve-month price objectives for Zymeworks' stock. Their forecasts range from $23.00 to $49.00. On average, they expect Zymeworks' share price to reach $36.57 in the next twelve months. This suggests a possible upside of 30.1% from the stock's current price. View Analyst Price Targets for Zymeworks.

What is the consensus analysts' recommendation for Zymeworks?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating, 5 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zymeworks.

Has Zymeworks been receiving favorable news coverage?

Headlines about ZYME stock have trended extremely negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zymeworks earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Zymeworks.

Are investors shorting Zymeworks?

Zymeworks saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 835,500 shares, an increase of 11.7% from the August 30th total of 748,300 shares. Based on an average daily trading volume, of 243,700 shares, the days-to-cover ratio is currently 3.4 days. Approximately 2.7% of the company's stock are sold short. View Zymeworks' Current Options Chain.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Who are Zymeworks' key executives?

Zymeworks' management team includes the folowing people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 47)
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Chief Financial Officer (Age 47)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 56)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 56)
  • Dr. Surjit Dixit, VP of Technology (Age 46)

When did Zymeworks IPO?

(ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Truvestments Capital LLC (0.00%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Eli & Co Lilly and Neil A Klompas. View Institutional Ownership Trends for Zymeworks.

Which institutional investors are buying Zymeworks stock?

ZYME stock was purchased by a variety of institutional investors in the last quarter, including Truvestments Capital LLC. View Insider Buying and Selling for Zymeworks.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $28.12.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $1.11 billion and generates $53.02 million in revenue each year. The company earns $-36,560,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Zymeworks employs 180 workers across the globe.View Additional Information About Zymeworks.

What is Zymeworks' official website?

The official website for Zymeworks is http://www.zymeworks.com/.

How can I contact Zymeworks?

Zymeworks' mailing address is 540-1385 WEST 8TH AVENUE, Vancouver A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]


MarketBeat Community Rating for Zymeworks (NYSE ZYME)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  154 (Vote Underperform)
Total Votes:  341
MarketBeat's community ratings are surveys of what our community members think about Zymeworks and other stocks. Vote "Outperform" if you believe ZYME will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZYME will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Featured Article: What is the Coverage Ratio?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel